Showing results (211-220 of 446) with videos related to
Sort By:
Pageof 45
Health Policy (Amsterdam, Netherlands)|April 2, 2026
An essential medicines list in Ireland: A qualitative interview study of interest-holdersJames Larkin, Matthew Preteroti, Logan T Murry, et al.BMC Cancer|December 21, 2018
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analysesIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, et al.Journal of Nephrology|November 1, 2025
Green haemodialysis: comparison of dialysis bags versus fresenius granumix at the AOU Policlinico di Modena, ItalyJames Larkin, Gaetano Alfano, Giulia Ligabue, et al.Nature Genetics|July 5, 2024
Saturation genome editing maps the functional spectrum of pathogenic VHL allelesMegan Buckley, Chloé Terwagne, Athina Ganner, et al.BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.European Journal of Cancer (Oxford, England : 1990)|August 30, 2025
Uveal Melanoma UK national guidelines: 2023 updateThomas J Carter, Jack Broadfoot, Sarah E Coupland, et al.Journal for Immunotherapy of Cancer|June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn Haanen, Marc Ernstoff, Yinghong Wang, et al.American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.Expert Opinion on Pharmacotherapy|December 22, 2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysisJames Larkin, Abby Paine, Indra Tumur, et al.Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.Pageof 45